Vision Capital Management Inc. Sells 453 Shares of Illumina, Inc. (NASDAQ:ILMN)

Vision Capital Management Inc. lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,307 shares of the life sciences company’s stock after selling 453 shares during the period. Vision Capital Management Inc.’s holdings in Illumina were worth $442,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Stratos Wealth Partners LTD. lifted its stake in Illumina by 2.5% during the 4th quarter. Stratos Wealth Partners LTD. now owns 6,534 shares of the life sciences company’s stock valued at $873,000 after acquiring an additional 160 shares during the period. E. Ohman J or Asset Management AB lifted its stake in shares of Illumina by 7.7% in the 4th quarter. E. Ohman J or Asset Management AB now owns 6,965 shares of the life sciences company’s stock worth $931,000 after purchasing an additional 500 shares during the period. Mather Group LLC. lifted its stake in shares of Illumina by 432.5% in the 4th quarter. Mather Group LLC. now owns 820 shares of the life sciences company’s stock worth $110,000 after purchasing an additional 666 shares during the period. Trust Point Inc. bought a new position in shares of Illumina in the 4th quarter worth approximately $235,000. Finally, Jennison Associates LLC lifted its stake in shares of Illumina by 0.3% in the 4th quarter. Jennison Associates LLC now owns 288,943 shares of the life sciences company’s stock worth $38,611,000 after purchasing an additional 881 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 0.4 %

ILMN stock opened at $124.68 on Thursday. The firm has a fifty day moving average price of $138.19 and a 200 day moving average price of $135.50. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the firm posted $0.33 earnings per share. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. Sell-side analysts forecast that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of several recent research reports. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. Morgan Stanley lowered their price objective on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.